Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

Antibiotics Market Size Worth $57.99 Billion By 2028 | CAGR: 4.5%: Grand View Research, Inc.

Published

on

 

The global antibiotics market size is expected to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.5% from 2021 to 2028. High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market. Moreover, rising awareness among patients and healthcare professionals and increasing involvement of regulatory bodies in the R&D activities of new therapies to treat infectious diseases are expected to propel the market growth over the forecast period.

Key suggestions from the report:

  • By action mechanism, the cell wall synthesis inhibitors segment accounted for the largest share of 52.1% in 2020 and is anticipated to maintain its lead over the forecast period
  • Based on drug class, the cephalosporin segment held the second-largest share in 2020. Pipeline candidates in cephalosporin drug class such as Fetroja (cefiderocol), cefilavancin, and ceftobiprole are anticipated to drive the segment in the forecast period
  • The others’ drug class segment is expected to grow at the fastest rate during the forecast period. The segment consists of various existing classes of antibiotics as well as some newly developed drugs, such as tetracycline, carbapenem, imidazole, peptides, lincosamides, and monoclonal antibodies
  • Asia Pacific was the largest regional market in 2020 and is expected to witness the fastest growth in the coming years owing to the rising consumption of antibiotics and high disease prevalence
  • North America emerged as the second-largest regional market in 2020 owing to government initiatives for the development of new therapies and better reimbursement scenario

Read 120 page research report with ToC on “Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA), By Action Mechanism, And Segment Forecasts, 2021 – 2028” at: https://www.grandviewresearch.com/industry-analysis/antibiotic-market

An increasing number of public-private collaborations, wherein funding and innovative R&D approaches are provided by public agencies to firms developing antibiotics, is expected to boost the product pipeline. For instance, in December 2018, Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited announced an agreement with GARDP for the development of novel antibacterial compounds.

Betterment in the approval process of antibiotic drugs is expected to boost the market growth over the forecast period. In February 2020, Merck received acceptance for a review of supplemental New Drug Application (sNDA) from the U.S. FDA for RECARBRIO (imipenem, cilastatin, and relebactam) intended for HABP/VABP. This submission is anticipated to reinforce the continued dedication of the company to R&D pertaining to antibiotic therapies that address unmet medical needs.

Government reforms such as the Generating Antibiotics Incentives Now Act in the U.S. are projected to propel market growth in the coming years. This is further expected to facilitate the development process of advanced drugs. According to the Pew Charitable Trusts, about 30% of the outpatient oral antibiotic drug prescriptions are unnecessary and most of these prescriptions are for disease conditions against which antibiotics are not significantly effective, such as non-bacterial infections and acute respiratory conditions.

The market is highly competitive and major market players have almost similar market share. Pharmaceutical players are adopting strategies, including mergers & acquisitions, collaborations, and strategic alliances, to gain a competitive advantage. The major pharmaceutical companies are collaborating for developing novel therapies to reduce the cost burden of the drug development process. In December 2019, Appili Therapeutics signed an agreement with Saptalis Pharmaceuticals for the reformulation of antibiotic metronidazole. According to the agreement, Saptalis will be responsible for manufacturing, marketing of ATI-1501 in the United States. Moreover, in October 2018, Paratek Pharmaceuticals, Inc. entered into a license agreement for the development and commercialization of Seysara (sarecyline) with Allergan.

A group of key pharmaceutical players has launched AMR Action Fund worth USD 1 billion in July 2020. This fund is expected to support the research of innovative and novel antibiotics and is formed in collaboration with the European Investment Bank, the Wellcome Trust, and the World Health Organization.

Due to the lack of commercial success for newly developed antimicrobial drugs, government and non-government bodies have adopted strategies to incentivize antibiotic drug R&D activities. For instance, the government in alliance with BARDA is supporting several companies to boost the R&D activities in new therapies for infectious diseases. BARDA has also been associated with pharmaceutical companies, such as GSK, Tetraphase, and Basilea Astra Zeneca. CARB-X is investing around USD 109 million to support the early-stage development of potential therapeutic candidates.

Grand View Research has segmented the global antibiotics market on the basis of action mechanism, drug class, and region:

Advertisement
  • Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2017 – 2028)
    • Cell Wall Synthesis Inhibitors
    • Protein Synthesis Inhibitors
    • DNA Synthesis Inhibitors
    • RNA Synthesis Inhibitors
    • Mycolic Acid Inhibitors
    • Others
  • Antibiotics Drug Class Outlook (Revenue, USD Million, 2017 – 2028)
    • Cephalosporin
    • Penicillin
    • Fluoroquinolone
    • Macrolide
    • Carbapenem
    • Aminoglycoside
    • Sulfonamide
    • 7-ACA
    • Others
  • Antibiotics Regional Outlook (Revenue, USD Million, 2017 – 2028)
    • North America
      • U.S
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • India
      • China
      • Japan
      • Thailand
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa

List of Key Players of Antibiotics Market

  • Merck & Co., Inc.
  • Allergan plc (AbbVie)
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Melinta Therapeutics
  • Basilea Pharmaceutica Ltd.
  • Tetraphase Pharmaceuticals
  • Paratek Pharmaceuticals, Inc.
  • Nabriva Therapeutics plc
  • Spero Therapeutics

Find more research reports on Pharmaceuticals Industry, by Grand View Research:

  • Monoclonal Antibodies Market  The global monoclonal antibodies market accounted for USD 85.4 billion in 2015 and is expected to exhibit a growth rate of 5.7% over the forecast period.
  • Animal Feed Additives Market  The global animal feed additives market size was USD 37.83 billion in 2019 and is projected to expand at a CAGR of 3.8% from 2020 to 2027.
  • Crohn’s Disease Therapeutics Market  The global Crohn’s disease therapeutics market size was estimated at USD 3.8 billion in 2016 and is expected to register a CAGR of 2.4% during the forecast period.

Fintech PR

Redefining Financial Frontiers: Nucleus Software Celebrates 30 Years with Synapse 2024 in Singapore

Published

on

redefining-financial-frontiers:-nucleus-software-celebrates-30-years-with-synapse-2024-in-singapore

SINGAPORE, Nov. 23, 2024 /PRNewswire/ — The thriving IndiaSingapore partnership in banking and technology reached a new milestone as Nucleus Software celebrated 30 years of transformative innovation at Synapse 2024, held in Singapore. The event underscored the company’s role in redefining financial services across Southeast Asia (SEA) and the globe, bringing together leaders in finance and technology to explore a shared vision for the future of banking.

Synapse 2024 celebrated 30 years of Nucleus Software’s leadership in driving transformative change across Singapore and Southeast Asia’s financial ecosystem. The event also shone a spotlight on the Global Finance & Technology Network (GFTN), an initiative supported by the Monetary Authority of Singapore (MAS) to champion responsible technology adoption. The event highlighted the deepening synergies between India and Singapore, driven by their shared commitment to innovation, cross-border collaboration, and financial inclusion. As the financial services sector undergoes rapid evolution with advancements in artificial intelligence, blockchain, and digital banking, these partnerships are setting the stage for a more connected, resilient, and inclusive global ecosystem.

Vishnu R. Dusad, Co-founder and Managing Director of Nucleus Software, reflected on the milestone: “For over 30 years, we’ve had the privilege of aligning our journey with Singapore’s ascent as a global financial powerhouse. Back in 1994, when we chose to go East instead of West, it was a bold and emotional decision—guided by our belief in Singapore as a hub for innovation and collaboration. We saw then what remains true today: Singapore is at the heart of the global financial landscape, a place where new ideas take root, and partnerships thrive.”

The event brought together a distinguished array of participants, highlighting the transformative potential of IndiaSingapore collaboration. Mr. Piyush Gupta, CEO of DBS Group and the Guest of Honor, set the tone for the event with his opening remarks, emphasizing the transformative role of big tech in reimagining scalable, customer-centric financial services in the digital age.

Following his address, key speakers enriched the discussions with their insights. Mr. Sopnendu Mohanty, Chief Fintech Officer at the Monetary Authority of Singapore and Group CEO-Designate of The Global Finance & Technology Network (GFTN), underlined the importance of fostering responsible technology adoption and building inclusive financial ecosystems. Mr. Vinod Rai, globally respected public policy expert, Distinguished Visiting Research Fellow at the National University of Singapore, and former Comptroller and Auditor General of India, shared his perspectives on governance and policy frameworks in financial systems. Mr. S.M. Acharya, Chairman of Nucleus Software and former Defence Secretary of India, offered a visionary outlook on leveraging technology to modernize and secure banking frameworks. Finally, Mr. Pieter Franken, Co-founder and Director of GFTN (Japan), a global FinTech pioneer and deep tech innovator, discussed the future of decentralized finance and its implications for the financial sector.

The event showcased the transformative role of technology in global financial systems, emphasizing innovations that set benchmarks for scalability and inclusivity. Panelists discussed the importance of localized solutions, the challenges of cross-border integration, and leveraging dual business models to optimize capital and foster public participation. The dialogue highlighted the need for common standards, unified frameworks like APIs, and collaborative efforts to accelerate financial inclusion and drive global connectivity in the digital age.

For 30 years, Nucleus Software has consistently introduced advanced lending and banking solutions that support financial institutions’ evolving needs in Singapore and South East Asia. Driven by lean development methodologies like Acceptance Test-Driven Development (ATDD) and Continuous Integration/Continuous Delivery (CICD), Nucleus Software continues to push boundaries in efficient, flexible, and secure financial technology.

Advertisement

Photo: https://mma.prnewswire.com/media/2565374/Synapse_2024.jpg
Logo: https://mma.prnewswire.com/media/2565373/Nucleus_Software_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/redefining-financial-frontiers-nucleus-software-celebrates-30-years-with-synapse-2024-in-singapore-302314485.html

Continue Reading

Fintech PR

ROYAL CANADIAN MINT REPORTS PROFITS AND PERFORMANCE FOR Q3 2024

Published

on

royal-canadian-mint-reports-profits-and-performance-for-q3-2024

OTTAWA, ON, Nov. 22, 2024 /PRNewswire/ — The Royal Canadian Mint (the “Mint”) announces its financial results for the third quarter of 2024 that provide insight into its activities, the markets influencing its businesses and its expectations for the next 12 months.

“As the markets continue to change, the Mint is proving its ability to seize on new opportunities thanks to its diversified structure and flexible business strategy” said Marie Lemay, President and CEO of the Royal Canadian Mint. 

The financial results should be read in conjunction with the Mint’s annual report available at www.mint.ca . All monetary amounts are expressed in Canadian dollars, unless otherwise indicated.

Financial and Operational Highlights

  • The financial results for the third quarter of 2024 were ahead of target and higher than 2023 levels. Higher gold market pricing and foreign circulation volumes combined with lower fixed costs were the main drivers for the quarter over quarter increase.  These increases were partially offset by lower than expected bullion volumes from the continued soft demand in the global bullion market. The Mint expects to meet its financial goals for 2024, as set out in its 2024-2028 Corporate Plan, the Mint’s Leadership team continues to actively monitor its status.
  • Consolidated revenue decreased to $252.7 million in 2024 (2023 – $360.6 million). 
    Revenue from the Precious Metals business decreased to $217.6 million in 2024
    (2023 – $328.4 million):
    • Gold bullion volumes decreased 38% quarter over quarter to 106.1 thousand ounces (2023 – 170.1 thousand ounces) while silver bullion volumes decreased 20% to 2.7 million ounces (2023 – 3.4 million ounces).
    • Gold and silver market prices increased quarter over quarter by 27% and 23%, respectively.
    • Sales of numismatic products decreased 12% quarter over quarter mainly due to the high demand in 2023 for the Queen Elizabeth II’s Reign products.
  • Revenue from the Circulation business increased to $35.1 million in 2024 
    (2023 – $32.2 million):
    • Revenue from the Foreign Circulation business increased 77% quarter over quarter, a reflection of higher volumes produced and shipped in 2024 as compared to 2023.
    • Revenue from Canadian coin circulation products and services decreased 12% quarter over quarter as fewer coins were required to replenish inventories, combined with lower program fees in accordance with the memorandum of understanding with the Department of Finance.
  • Overall, operating expenses decreased 27% quarter over quarter to $28.3 million (2023 – $36.0 million) mainly due to planned reductions in consulting and workforce expenses.

Consolidated results and financial performance 
(in millions) 

13 weeks ended

39 weeks ended

      Change

         Change

September
28, 2024

September
30, 2023

Advertisement

$

%

September
28, 2024

September

 30, 2023

$

%

Revenue

$

252.7

Advertisement

$ 360.6

(107.9)

(30)

$    861.2

$ 1,841.8

(980.6)

(53)

Profit (loss) for the

     period

$

Advertisement

 

5.7

 

$   (5.8)

 

11.5

 

 

(198)

Advertisement

 

$      24.1

 

$      15.0

 

9.1

 

61

Profit (loss) before
     income tax and
     other items 1

$

Advertisement

1.4

$   (8.7)

10.1

 

(116)

$      12.3

$      23.4

(11.1)

(47)

Advertisement

Profit (loss) before
     income tax and
     other items margin2

0.6 %

(2.4) %

1.4 %

1.3 %

(1) Profit (loss) before income tax and other items is a non-GAAP financial measure. A reconciliation from profit for the period to profit before income tax and other items is included on page 13 of the Mint’s 2024 Third Quarter Report.

(2) Profit (loss) before income tax and other items margin is a non-GAAP financial measure and its calculation is based on profit before income tax and other items.

 

As at

             September 28, 2024

Advertisement

December 31, 2023

$ Change

% Change

Cash

$

58.4

$

59.8

(1.4)

(2)

Advertisement

Inventories

$

71.5

$

68.8

2.7

4

Capital assets

$

174.2

Advertisement

$

173.0

1.2

1

Total assets

$

376.8

$

380.4

(3.6)

Advertisement

(1)

Working capital

$

99.2

$

97.8

1.4

1

As part of its enterprise risk management program, the Mint continues to actively monitor its global supply chain and logistics networks in support of its continued operations. Despite its best efforts, the Mint expects changes in the macro-economic environment and other external events around the globe to continue to impact its performance in 2024. The Mint continues to mitigate potential risks as they arise through its enterprise risk management process.

To read more of the Mint’s Third Quarter Report for 2024, please visit www.mint.ca.

Advertisement

About the Royal Canadian Mint
The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of Canada’s circulation coins. The Mint is one of the largest and most versatile mints in the world, producing award-winning collector coins, market-leading bullion products, as well as Canada’s prestigious military and civilian honours.  As an established London and COMEX Good Delivery refiner, the Mint also offers a full spectrum of best-in-class gold and silver refining services.  As an organization that strives to take better care of the environment, to cultivate safe and inclusive workplaces and to make a positive impact on the communities where it operates, the Mint integrates environmental, social and governance practices in every aspect of its operations. 

For more information on the Mint, its products and services, visit www.mint.ca. Follow the Mint on LinkedInFacebook and Instagram

FORWARD LOOKING STATEMENTS AND NON-GAAP FINANCIAL MEASURES

This Earnings Release contains non-GAAP financial measures that are clearly denoted where presented. Non-GAAP financial measures are not standardized under International Financial Reporting Standards (IFRS) and might not be comparable to similar financial measures disclosed by other corporations reporting under IFRS.

This Earnings Release contains forward-looking statements that reflect management’s expectations regarding the Mint’s objectives, plans, strategies, future growth, results of operations, performance, and business prospects and opportunities.  Forward-looking statements are typically identified by words or phrases such as “plans”, “anticipates”, “expects”, “believes”, “estimates”, “intends”, and other similar expressions. These forward-looking statements are not facts, but only estimates regarding expected growth, results of operations, performance, business prospects and opportunities (assumptions). While management considers these assumptions to be reasonable based on available information, they may prove to be incorrect. These estimates of future results are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from what the Mint expects. These risks, uncertainties and other factors include, but are not limited to, those risks and uncertainties set forth in the Risks to Performance section of the Management Discussion and Analysis in the Mint’s 2023 annual report, as well as in Note 9 – Financial Instruments and Financial Risk Management to the Mint’s Audited Consolidated Financial Statements for the year ended December 31, 2023. The forward-looking statements included in this Earnings Release are made only as of November 20, 2024 and the Mint does not undertake to publicly update these statements to reflect new information, future events or changes in circumstances or for any other reason after this date.

For more information, please contact: Alex Reeves, Senior Manager, Public Affairs, Tel: (613) 884-6370, [email protected] 

 

View original content:https://www.prnewswire.co.uk/news-releases/royal-canadian-mint-reports-profits-and-performance-for-q3-2024-302314428.html

Continue Reading

Fintech PR

OIVE and ViniPortugal celebrate closing of joint campaign that reached 100 million consumers

Published

on

MADRID and PORTO, Portugal, Nov. 22, 2024 /PRNewswire/ — For three years, A Shared Passion showed European consumers the quality and unparalleled versatility of Iberian wines. The program reached over 100 million consumers with advertising in airports, train stations, press trips, digital content, and other actions with opinion leaders.

The wine interprofessionals of Spain (OIVE) and Portugal (ViniPortugal) celebrated the closing of their ambitious joint campaign A Shared Passion with flagship events in Madrid and Porto. The closing event in Spain took place in Madrid’s iconic Calle Alcalá, while in Portugal, the World of Wine (WOW) in Porto was the perfect setting to present the achievements of the international collaboration. Both ceremonies were very well received by the press and the wine sector, highlighting the impact of the promotional actions that reached more than 79.2 million travelers in key transport infrastructures. 

The campaign included 22 study trips, taking 150 specialized journalists to explore the world of wine in both countries and generating publications that reached nearly 15 million European consumers.

On social media, the A Shared Passion profile on Instagram exceeded 15,000 followers, consolidating its presence in the digital sphere. In addition, exclusive activities such as workshops and VIP dinners contributed significantly to this initiative’s global impact. 

The final events were honored by the presence of opinion leaders, such as Masters of Wine Pedro Ballesteros and Dirceu Vianna Júnior, who moderated round tables with the presidents of OIVE, Fernando Ezquerro, and ViniPortugal, Frederico Falcão. The conference concluded with masterclasses that highlighted Spain and Portugal’s extraordinary oenological diversity, reinforcing the relevance of the sector in the economic, social, and environmental sustainability of both countries. 

With funding from the European Union, A Shared Passion highlighted not only the quality and authenticity of Iberian wines but also their strategic role in the sustainable development of numerous municipalities. This initiative underlines the passion with which Spanish and Portuguese wines are made, reflecting their rich traditions and commitment to the future.

For more information: www.asharedpassion.com

Video: https://mma.prnewswire.com/media/2565600/ViniPortugal_and_OIVE.mp4

Advertisement

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/oive-and-viniportugal-celebrate-closing-of-joint-campaign-that-reached-100-million-consumers-302314339.html

Continue Reading

Trending